Professor Srinivasan Madhusudan trained in Medical Oncology at Oxford, England. As a Cancer Research UK Clinical Research Fellow he completed his Ph.D. work at the Weatherall Institute of Molecular Medicine, Oxford. In 2007, he moved to Nottingham as a Clinical Associate Professor in Medical Oncology. In 2011, he was awarded the prestigious 'Goulstonian Lectureship' by the Royal College of Physicians, London, an award made to the most academically outstanding Young Fellow of the College. In 2016, he was promoted to Professor of Medical Oncology and is currently the Head of Service for Oncology at Nottingham University Hospitals. As an academic oncologist, he is very active in cancer clinical trials, leads the Nottingham Cancer Clinical Trials Unit and currently National Institute for Health Research (NIHR) Divisional Lead for Cancer (East Midlands).
Prof Madhusudan's pre-clinical laboratory research is focused on the evaluation of DNA repair factors as prognostic, predictive and therapeutic targets in cancer. Research in his laboratory has received funding from the Medical Research Council, Breast Cancer Now and Target Ovarian Cancer. Prof Madhusudan currently works on the clinical translational aspects of DNA repair. His group has identified novel biomarkers, potential drug targets and newer approaches for personalized treatment strategies targeting DNA repair in cancer. Prof Madhusudan has published over 100 research articles, edited two books and contributed to several book chapters. In recognition of his outstanding translational cancer research, he was recently awarded the prestigious 'Lady Estelle Wolfson lectureship in Translational Medicine for 2019' by the Royal College of Physicians of London.
Clinical trials; DNA repair; translational oncology; biomarkers; drug discovery; breast cancers; upper GI cancers; ovarian cancers; brain tumours.
ARORA A, PARVATHANENI S, ALESKANDARANY MA, AGARWAL D, ALI R, ABDEL-FATAH TM, GREEN AR, BALL GR, RAKHA EA, ELLIS IO, SHARMA S and MADHUSUDAN S, 2016. Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers. Molecular cancer therapeutics.
ALSUBHI N, MIDDLETON F, ABDEL-FATAH TMA, STEPHENS P, DOHERTY R, ARORA A, MOSELEY PM, CHAN SYT, ALESKANDARANY MA, GREEN AR, RAKHA EA, ELLIS IO, MARTIN SG, CURTIN NJ and MADHUSUDAN S, 2016. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer Molecular Oncology. 10(2), 213-223 ARORA, A., ABDEL-FATAH, T. M., AGARWAL, D., DOHERTY, R., CROTEAU, D. L., MOSELEY, P. M., HAMEED, K., GREEN, A., ALESKANDARANY, M. A., RAKHA, E. A., PATTERSON, K., BALL, G., CHAN, S. Y., ELLIS, I. O., BOHR, V. A., BRYANT, H. E. and MADHUSUDAN, S., 2016. Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers: Carcinogenesis Carcinogenesis. 37(1), 63-71
ARORA, A., AGARWAL, D., ABDEL-FATAH, T.M.A., LU, H., CROTEAU, D.L., MOSELEY, P., ALESKANDARANY, M.A., GREEN, A.R., BALL, G., RAKHA, E.A., CHAN, S.Y.T., ELLIS, I.O., WANG, L.L., ZHAO, Y., BALAJEE, A.S., BOHR, V.A. and MADHUSUDAN, S., 2016. RECQL4 helicase has oncogenic potential in sporadic breast cancers Journal of Pathology. 238(4), 495-501